The genomic landscape of teenage and young adult T-cell acute lymphoblastic leukemia
- PMID: 34080325
- PMCID: PMC8290240
- DOI: 10.1002/cam4.4024
The genomic landscape of teenage and young adult T-cell acute lymphoblastic leukemia
Abstract
Background: Treatment on risk adapted intensive pediatric protocols has improved outcome for teenagers and young adults (TYA) with T-cell acute lymphoblastic leukemia (T-ALL). Understanding the biology of disease in this age group and the genetic basis of relapse is a key goal as patients with relapsed/refractory disease have poor outcomes with conventional chemotherapy and novel molecular targets are required. This study examines the question of whether TYA T-ALL has a specific biological-molecular profile distinct from pediatric or adult T-ALL.
Methods: Genomic characterization was undertaken of a retrospective discovery cohort of 80 patients aged 15-26 years with primary or relapsed T-ALL, using a combination of Genome-Wide Human SNP Array 6.0, targeted gene mutation and promoter methylation analyses. Findings were confirmed by MLPA, real-time quantitative PCR, and FISH. Whole Exome Sequencing was performed in 4 patients with matched presentation and relapse to model clonal evolution. A prevalence analysis was performed on a final data set of 1,792 individual cases to identify genetic lesions with age specific frequency patterns, including 972 pediatric (1-14 years), 439 TYA (15-24 years) and 381 adult (≥25 years) cases. These cases were extracted from 19 publications with comparable genomic data identified through a PubMed search.
Results: Genomic characterization of this large cohort of TYA T-ALL patients identified recurrent isochromosome 7q i(7q) in our discovery cohort (n = 3). Prevalence analysis did not identify any age specific genetic abnormalities. Genomic analysis of 6 pairs of matched presentation - relapsed T-ALL established that all relapses were clonally related to the initial leukemia. Whole exome sequencing analysis revealed recurrent, targetable, mutations disrupting NOTCH, PI3K/AKT/mTOR, FLT3, NRAS as well as drug metabolism pathways.
Conclusions: All genetic aberrations in TYA T-ALL occurred with an incidence similar or intermediate to that reported in the pediatric and adult literature, demonstrating that overall TYA T-ALL exhibits a transitional genomic profile. Analysis of matched presentation - relapse supported the hypothesis that relapse is driven by the Darwinian evolution of sub-clones associated with drug resistance (NT5C2 and TP53 mutations) and re-iterative mutation of known key T-ALL drivers, including NOTCH1.
Keywords: T-ALL; clonal selection; genomics; relapse; teenagers and young adults.
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
-
- Beldjord K, Chevret S, Asnafi V, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014;123(24):3739‐3749. - PubMed
-
- Patrick K, Wade R, Goulden N, et al. Outcome for children and young people with early T‐cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol. 2014;166(3):421‐424. - PubMed
-
- Patrick K, Wade R, Goulden N, et al. Improved outcome for children and young people with T‐acute lymphoblastic leukaemia: results of the UKALL 2003 trial. Blood. 2014;124(21):3702.
-
- Sellar RS, Rowntree C, Vora AJ, et al. Relapse in teenage and young adult patients treated on a paediatric minimal residual disease stratified ALL treatment protocol is associated with a poor outcome: results from UKALL2003. Br J Haematol. 2018;181(4):515‐522. - PubMed
Publication types
MeSH terms
Grants and funding
- KKLF417/Kay Kendall Leukaemia Fund
- Fundação do Cancer, SwissBridge Fund
- 134253/The Hungarian National Research, Development and Innovation Office-NKFIH
- E-26/202.577/2019/FAPERJ
- BO/00320/18/5/Hungarian Academy of Sciences
- 310877/2019-5/INCA, CNPq
- ÚNKP-20-5-SE-22/New National Excellence Program of the Ministry for Innovation and Technology
- The Institute of Cancer Research
- Lady Tata Memorial Trust-LTMT International Award for Research in Leukaemia and the Ministry of Health, INCA-Brazil
- 2011/01/The European Hematology Association-EHA Partner Fellowship
- 119950/The Hungarian National Research, Development and Innovation Office-NKFIH
- Leukaemia & Lymphoma Research
- 739593/EU's Horizon 2020 Research and Innovation Program
- 105104/Z/14/Z/WT_/Wellcome Trust/United Kingdom
- Bloodwise
- E-26/110.712/2012/FAPERJ
- 301594/2015-5/INCA, CNPq
- WT_/Wellcome Trust/United Kingdom
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
